537705-08-1

Usage

Uses

Used in Pharmaceutical Industry:
CP-724714 is used as a targeted therapy agent for the treatment of cancer. Its high selectivity for HER2/ErbB2 and EGFR proteins makes it a promising candidate for the development of drugs that can specifically inhibit these proteins, which are often overexpressed in various types of cancer cells. This targeted approach can potentially lead to more effective treatments with fewer side effects compared to non-selective chemotherapy drugs.
Used in Cancer Research:
In the field of cancer research, CP-724714 can be used as a valuable tool to study the role of HER2/ErbB2 and EGFR proteins in cancer cell growth and progression. By inhibiting these proteins, researchers can gain insights into the molecular mechanisms underlying cancer development and identify potential therapeutic targets for the development of new cancer treatments.
Used in Drug Development:
CP-724714 can be utilized in the development of new drugs for the treatment of various types of cancer, particularly those that are driven by the overexpression or dysregulation of HER2/ErbB2 and EGFR proteins. Its potent and selective inhibition of these proteins can be leveraged to design drugs that specifically target cancer cells, potentially leading to improved treatment outcomes and reduced side effects for patients.
Used in Drug Delivery Systems:
Similar to gallotannin, CP-724714 can also benefit from the development of novel drug delivery systems to enhance its applications and efficacy against cancer cells. Various organic and metallic nanoparticles can be employed as carriers for CP-724714 delivery, aiming to improve its delivery, bioavailability, and therapeutic outcomes.

Biological Activity

cp-724714 is an inhibitor of erbb2 and egfr kinases with ic50 values of 10±3 nmol/l and 6,400±2,100 nmol/l, respectively [1].in the in vitro cell cycle assay, cp-724714 cause a g1 block of the her2-amplified bt-474 breast cancer cells due to its inhibition of erbb2. cp-724714 at 1 ?mol/l can also reduce the level of phospho-erbb2 in these cells. in in vivo assay, cp-724714 cause a concentration-dependent reduction of tumor erbb2 receptor phosphorylation in athymic mice bearing fre-erbb2xenografts. cp-724714 treatments also resulted in a time- and dose-dependent induction of tumor cell apoptosis. in two human breast carcinoma models, bt-474 and mda-mb-453, which are her2 amplified and highly overexpress erbb2, cp-724714 is found to produce a dose-dependent inhibition of xenograft growth. in addition, cp-724,714 treatments induce reduction of downstream erbb2 rtk signaling. on the basis of these, cp-724,714 was advanced to phase i clinical trials and is potentially another option for her2-driven breast cancer [1].

references

[1] jitesh p. jani, richard s. finn, mary campbell, et al. discovery and pharmacologic characterization of cp-724714, a selective erbb2 tyrosine kinase inhibitor. cancer research. 2007 (67): 9887-9893.

Upstream product

• 38870-89-2 Methoxyacetyl chloride 
• 537705-05-8 6-iodo-N-(3-methyl-4-((6-methylpyridin-3-yl)oxy)phenyl)quinazolin-4-amine 
• 537705-07-0 N-propargyl-2-methoxyacetamide 
• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 13290-74-9 1-chloro-2-methyl-4-nitrobenzene 
• 697299-78-8 2-methyl-5-(2-methyl-4-nitrophenoxy)pyridine 
• 537705-06-9 3-(2-methyl-4-aminophenoxy)-6-methylpyridine 
• 98556-31-1 4-chloro-6-iodoquinazoline 
• 5326-47-6 2-amino-5-iodobenzoic acid 
• 16064-08-7 6-iodo-4-hydroxyquinazoline 
• 486393-59-3 N-allyl-2-methoxyacetamide 
• 537705-10-5 (6-iodoquinazolin-4-yl)-[3-methyl-4-(6-methylpyridin-3-yloxy)phenyl]amine hydrochloride 
• 625-45-6 2-methoxyacetic acid 
• 3375-31-3 palladium diacetate 

Relevant academic research and scientific papers

Highly functionalised sulfur-based silica scavengers for the efficient removal of palladium species from active pharmaceutical ingredients

The use of multidentate sulfur-based silica scavengers 1,2, and 3 as highly effective adsorbents for the removal of precious metals, specifically palladium residues in this paper, from highly functionalised synthetic intermediates and APIs is described. The synthesis and purification of the polar and electron-rich reaction products, containing multiple functional groups, from palladium-catalysed removals of commonly used protecting groups such as benzyl, benzyloxycarbonyl, and allyloxycarbonyl and Sonogashira, Suzuki, Heck, and Buchwald-Hartwig coupling reactions is reported. The significant levels of residual palladium species, typically associated with these reaction products, are successfully and rapidly removed to below acceptable regulatory levels, of less than 5 ppm, by simple, unoptimised treatment with the designed silica scavengers at room temperature. Performance aspects, including broad solvent compatibility, excellent stability, and high metal affinity, combined with large-scale availability, ease of handling, and minimal loss of API make these silica scavengers particularly useful to process development groups.

COMBINATIONS OF ERBB2 INHIBITORS WITH OTHER THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER

This invention relates to a method of treatment of cancer with a combination of an additional therapeutic agent in mammals. This invention also relates to a kit useful in the treatment of abnormal cell growth in mammals, especially humans.

Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer

This invention relates to a method of treatment of cancer with a combination of an erbB2 ligand and an antibody, in mammals. More particularly, this invention relates to a method of treating cancer by administering an erbB2 ligand in combination with an erbB antibody. This invention also relates to a kit useful in the treatment of abnormal cell growth in mammals, especially humans.

Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide

Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide. A crystal form is useful in the synthesis of salts and complexes of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide. A crystal form also improves stability of tabletted or capsuled E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide as a drug product.

Evaluation of kilogram-scale Sonagashira, Suzuki, and Heck coupling routes to oncology candidate CP-724,714

The synthesis of the anti-cancer compound 2-methoxy-N-(3-{4-[3-methyl-4-(6- methyl-pyridin-3-yloxy)phenylamino]quinazolin-6-yl}-E-allyl)acetainide (CP-724,714) (1) on multikilogram scale using several different synthetic routes is described. Application of the Sonogashira, Suzuki, and Heck couplings to this synthesis was investigated to identify a safe, environmentally friendly, and robust process for the production of this drug candidate. A convergent and selective synthesis of the candidate was identified which utilizes a Heck coupling of a protected allylamine to install the critical olefin.

PROCESSES FOR THE PREPARATION OF N-((((PYRIDINYLOXY) -PHENYLAMINO) QUINAZOLINYL)- ALLYL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS WELL AS INTERMEDIATES OF SUCH PROCESSES AND PROCESSES FOR THE PREPARATION OF SUCH INTERMEDIATES

The invention relates to processes for preparing compounds of the formula (1) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R3, R4, R6 R11, R13 R14 R15, R16, R17, k, I, and m are as defined herein. The present invention also relates to intermediates represented by the formula (3a) wherin R4, and R5 are independently selected from hydrogen and C1-C6alkyl; each R13, R14, R15 and R16 is independently selected from hydrogen, C1-C6alkyl and CH2OH, R17 and R18 are independently C1-C6 alkyl, and k and I are independently an integer from 1 to 3, as well as to a process for preparing these intermediates.

COMPLEXES OF E-2-METHOXY-N-(3-{4-[3-METHYL-4-(6-METHYL-PYRIDIN-3-YLOXY)-PHENYLAMINO]-QUINAZOLIN-6-YL}-ALLYL)-ACETAMIDE, THEIR METHOD OF PRODUCTION, AND USE

The invention relates to complexes of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide having the following formula I: The invention also relates to pharmaceutical compositions containing the complexes of formula I. The invention further relates to methods of treating hyperproliferative diseases, such as cancers, in mammals, especially humans by administering the above complexes and to methods of preparing the above complexes.

Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth

The invention relates to processes for preparing compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R3, R4, R5, R11, m and p are as defined

Substituted bicyclic derivatives for the treatment of abnormal cell growth

The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R3, R4, R5, R11, m and p are as defined herein. The invention a